Skip to content

Quantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases

Quantitative Muscle Ultrasound as a Monitoring Tool of Disease Progression in Children With Inflammatory Myositis and Duchenne Muscular Dystrophy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03786913
Enrollment
48
Registered
2018-12-26
Start date
2016-03-08
Completion date
2019-02-02
Last updated
2019-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy, Inflammatory Myopathy

Keywords

Inflammatory myositis, Duchenne Muscular Dystrophy, Musculoskeletal ultrasound

Brief summary

The aim of our study is to Assess skeletal muscle structural status in children with inflammatory myositis and Duchenne muscular dystrophy using musculoskeletal ultrasound and to perform a longitudinal follow up of these changes over 2 years and to assess the relation between these findings with clinical parameters, functional scales, biochemical and electromyographic tests.

Detailed description

This study will be carried out on two groups: • Group (I): fifty children diagnosed to have duchenne muscular dystrophy and inflammatory myositis. Group (II): including 20 healthy children matching age and sex as control group. patients will be subjected to (A) Clinical evaluation 1. Complete history taking. 2. Thorough clinical examination. 3. Body mass index (BMI) assessment. 4. Quantitative muscle strength tests 5. Functional grading 6. Childhood Myositis Assessment Scale. 7 (B) Laboratory assessment: All patients will be subjected to the following measurements: 1. Serum creatine kinase levels (CK). 2. Serum Lactate dehydrogenase levels 3. Serum of Liver enzymes (SGOT& SGPT) levels. (C) Electromyographic (EMG) assessment: (D) Musculoskeletal ultrasound assessment (E) Statistical analysis

Interventions

DIAGNOSTIC_TESTQuantitative muscle ultrasound measurements

Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.

Sponsors

Benha University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 16 Years

Inclusion criteria

* children with Duchenne muscular dystrophy (DMD). Diagnosis with DMD was established according to DMD diagnostic criteria (Jennekens et al., 1991). * children with juvenile dermatomyositis (JDM) according to Bohan and Peter diagnostic criteria ( (Bohan and Peter, 1975).

Exclusion criteria

* Patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales. * If no final diagnosis could be established. * The presence of a concomitant illness that may result in peripheral neuropathy or myopathy.

Design outcomes

Primary

MeasureTime frameDescription
Kendall's manual muscle testing24 monthsKendall's 0 -10 point scale measures strength of each muscle group score 0 is the weakest (worst) and 10 is the strongest (best). The following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors (FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA)
Childhood myositis assessment scale24 monthsused to assess the severity of muscle involvement in children with dermatomyositis. The scores for the 14 items are summated to give a total score ranging from 0 (worst) to 52 (best)
Serum creatine kinase (CK) levels24 monthsCK measured in U/L using ELISA
Serum Lactate dehydrogenase (LDH) levels24 monthsCK measured in IU/L using ELISA
Aspartate aminotransferase (AST)24 MONTHSAST measured in U/L using ELISA
alanine aminotransferase (ALT)24 monthsALT measured in U/L using ELISA
motor unit potential (MUP) duration24 monthsquantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the MUP duration measured in milliseconds.
motor unit peak-to-peak amplitude24 monthsquantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the peak-to-peak amplitude measured in microvolt
motor unit area to amplitude ratio (AAR)24 monthsquantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the motor unit AAR .

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026